吉非替尼肝毒性的分子机制及药物防治研究进展

尹小婷; 栗敏; 沈继朵; 许二平; 白明<sup>*</sup>; 栗俞程<sup>*</sup>

引用本文:	尹小婷,栗敏,沈继朵,许二平,白明,栗俞程.吉非替尼肝毒性的分子机制及药物防治研究进展[J].中国现代应用药学,2023,40(15):2155-2160.
	YIN Xiaoting,LI Min,SHEN Jiduo,XU Erping,BAI Ming,LI Yucheng.Research Progress on Molecular Mechanism and Drug Prevention and Treatment of Gefitinib Hepatotoxicity[J].Chin J Mod Appl Pharm(中国现代应用药学),2023,40(15):2155-2160.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 1197次下载 867次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
吉非替尼肝毒性的分子机制及药物防治研究进展
尹小婷^1,2, 栗敏³, 沈继朵², 许二平¹, 白明¹, 栗俞程¹
1.河南中医药大学, 豫药全产业链研发河南省协同创新中心, 中医药科学院, 郑州 450046;2.河南中医药大学药学院, 郑州 450046;3.郑州人民医院肿瘤内科, 郑州 450008

摘要:

吉非替尼作为第一个上市的表皮生长因子受体酪氨酸激酶抑制剂，在非小细胞肺癌等恶性肿瘤的靶向治疗中具有重要作用，但该药会引发肝毒性等严重的不良反应，须停药进行保肝治疗，极大地影响肿瘤的治疗过程。但吉非替尼所致肝毒性的机制仍不清楚，临床治疗措施也十分有限。本文综述吉非替尼诱导肝毒性的分子机制以及临床常用治疗药物，为临床防治及合理用药提供科学依据。

关键词: 吉非替尼肝毒性分子机制药物防治

DOI：10.13748/j.cnki.issn1007-7693.20222016

分类号:R969.3

基金项目:国家自然科学基金项目(81973739)；河南中医药大学“仲景骨干学者”；河南省优秀青年科学基金(202300410249)

Research Progress on Molecular Mechanism and Drug Prevention and Treatment of Gefitinib Hepatotoxicity

YIN Xiaoting^1,2, LI Min³, SHEN Jiduo², XU Erping¹, BAI Ming¹, LI Yucheng¹

1.Henan University of traditional Chinese Medicine, Henan Collaborative Innovation Center for Research and Development on the Whole Industry Chain of Yu-Yao, Academy of Chinese Medical Sciences, Zhengzhou 450046, China;2.Henan University of traditional Chinese Medicine, Department of Pharmacy, Zhengzhou 450046, China;3.Department of Medical Oncology, Zhengzhou People's Hospital, Zhengzhou 450008, China

Abstract:

As the first marketed epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib plays an important role in the targeted therapy of malignant tumors such as non-small cell lung cancer, but this drug can cause serious adverse effects such as liver toxicity. If the reaction occurs, the drug must be stopped for liver protection treatment, which greatly affects the treatment process of cancer. However, the mechanism of gefitinib-induced hepatotoxicity is still unclear, and clinical treatment measures are very limited. This article aims to review the molecular mechanism of gefitinib-induced hepatotoxicity and the commonly used clinical therapeutic drugs, so as to provide scientific basis for clinical prevention and rational drug use.

Key words: gefitinib hepatotoxicity molecular mechanism drug prevention and treatment